Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of MDMA can be broken down into five components all of which progressively intensify proportional to dosage.
The general head space of MDMA is described by many as one of extreme mental stimulation, feelings of love or empathy and powerful euphoria. It contains a large number of typical psychedelic, entactogenic and stimulant cognitive effects.
The visual effects of MDMA have an occurrence rating that is more selective and less consistent than any of the traditional psychedelics. They can never be guaranteed to manifest themselves but are more likely to occur with chemically pure high dose MDMA experiences, towards the end of the experience and if the user has been smoking marijuana.
MDMA presents an array of visual enhancements which are mild in comparison to traditional psychedelics but still distinctively present.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of psilocin than LSD. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, mostly blue and grey in scheme, glossy in colour, equal in blurred and sharp edges and equal in rounded and angular corners. At higher dosages they are significantly more likely to result in states of Level 7A visual geometry over Level 7B. Many users report an almost menacing feeling, following a sinister and ominous style with a colour scheme that generally consists of greys and blues.
MDMA is capable of producing a unique range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.
The auditory effects of MDMA are common in their occurrence and exhibit a partial range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
MDMA has moderate to high abuse potential but a low potential for genuine psychological dependence, estimated at lower than 10% and rated three-fourths to four-fifths that of cannabis by expert panels. Compulsive redosing is commonly reported during experiences, and context-dependent psychological dependence may develop when use is linked to specific activities such as parties or raves.
Physical dependence potential is low, with MDMA often described as not physically addictive. However, approximately 60% of users experience withdrawal symptoms upon cessation, including fatigue, loss of appetite, depression, and difficulty concentrating. These symptoms are generally mild compared to substances with higher physical dependence potential.
The estimated fatal dose in humans is approximately 15 to 16 times a typical recreational dose. The lethal risk from a single dose is estimated at 1 death per 20,000 to 50,000 instances, or approximately 2 per 100,000 new users. Most MDMA-related fatalities involve multiple drugs rather than MDMA alone, with acute toxicity primarily caused by serotonin syndrome and sympathomimetic effects. Toxicity may be exacerbated by caffeine, a common adulterant.
| Species | Route | Value |
|---|---|---|
| mouse | IP | 97 mg/kg |
| rat | IP | 49 mg/kg |
| guinea pig | IP | 98 mg/kg |
Heavy or frequent use, particularly at higher doses, has been associated with neurotoxic damage to serotonergic axon terminals in striatal, hippocampal, prefrontal, and occipital regions; damage may persist for more than two years but appears partially reversible with abstinence. Typical recreational use at moderate doses and infrequent intervals presents less clear neurotoxicity risk.
Heavy or long-term use may increase the risk of valvular heart disease and primary pulmonary hypertension due to chronic activation of serotonin 5-HT2B receptors; acute cardiovascular stress including elevated heart rate and blood pressure occurs during intoxication.
Liver toxicity has been reported rarely with MDMA use; the liver is stressed during acute intoxication due to extensive hepatic metabolism.
Kidneys are stressed during MDMA use; individuals with pre-existing kidney disorders may be at higher risk of complications.
Psychotic episodes are rare but have been reported, typically at high doses or with heavy use. Possible psychological crises requiring hospitalization, including severe panic attacks and psychotic episodes, occur in a small minority of users. At higher doses, delirious external hallucinations may occur, which is not considered a typical or healthy response.
Seizures are rare but may occur in susceptible individuals, particularly at higher doses, with redosing, or in physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating. More common in smaller individuals and those with pre-existing epilepsy. A small number of users have reportedly experienced seizures after taking moderate amounts of pure MDMA.
MDMA was first synthesized in 1912 by German chemist Anton Köllisch while working at the pharmaceutical company Merck. Contrary to persistent myths about the compound being developed as an appetite suppressant or psychotherapy aid, it was actually created as an intermediate in the synthesis of…
UN Convention on Psychotropic Substances 1971 (Schedule I, added February 1986)
Reclassified to Schedule 8 as of July 1, 2023, allowing for limited authorized medical use. Personal quantities under 1.5 grams or 5 single doses have been decriminalized in the Australian Capital Territory since October 28, 2023.
Possession, production, and sale are prohibited under national drug legislation.
Controlled under the Controlled Drugs and Substances Act. Prior to the March 2012 Safe Streets and Communities Act, MDMA and amphetamines were classified under the less restrictive Schedule III.
Possession, production, and sale are prohibited under Danish drug control legislation.
Listed in Finland's controlled substances registry in the hard-drug category. Possession, production, and sale without authorization are illegal.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since August 1, 1986. Manufacturing, possessing, importing, exporting, buying, selling, procuring, or dispensing without a license is illegal.
Classified as a Schedule I controlled substance. Possession, production, and distribution are illegal.
Classified as a hard drug under the Opium Act. Sale, manufacture, and possession of large amounts are illegal. While possession of small quantities for personal use is technically still illegal, it is generally not prosecuted.
Classified under the most restrictive category in Norwegian drug legislation. Buying or possessing without a license is illegal.
Since July 2001 under Law 30/2000, personal possession of less than 1 gram is not a criminal offense. The substance may be confiscated and the individual referred to a dissuasion commission. Production, sale, and trafficking remain criminal offenses.
Possession, production, and sale are prohibited under Swedish drug control legislation.
Controlled under the Misuse of Drugs Act 1971, which was amended in 1977 to include ring-substituted amphetamines and further amended in 1985 to specifically reference MDMA. Class A carries the most severe penalties for possession, supply, and production.
Prohibited under the Suchtmittelgesetz (SMG). Possession, production, and sale are criminal offenses.
Listed under Portaria SVS/MS nº 344. Production, distribution, and possession are illegal.
Classified as a Schedule I controlled substance under national legislation.
Requires a prescription or license for legal possession. Unauthorized possession, production, and distribution are prohibited.
Classified as a narcotic substance under French law. Possession, purchase, sale, and manufacture are prohibited.
Listed in Tabella I of the controlled substances tables (Tabelle delle sostanze stupefacenti e psicotrope). Possession, purchase, and sale are prohibited.
Classified as a prohibited substance under national drug legislation.
Reclassified from the less restrictive Class B2 to Class B1 on August 2, 2005. Possession, manufacture, and supply carry significant criminal penalties.
Under Article 2999 of the Peruvian penal code, personal possession of up to 250 milligrams of MDMA is not considered a criminal offense. Production and sale remain illegal.
Classified as a Schedule I prohibited substance. Possession, production, and distribution are criminal offenses.
Specifically listed as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Classified as Schedule I under the Controlled Substances Act since July 1, 1985, initially on an emergency basis. Manufacturing, buying, possessing, or distributing without a DEA license is illegal. Despite an administrative law judge recommending Schedule III placement to allow medical use, the DEA director overruled and maintained Schedule I status.
27 sources cited
